Related Experiment Video
Updated: May 17, 2025
04:56
Author Spotlight: Deciphering Coagulation Disorders in Traumatic Brain Injury Patients
Published on: August 4, 2023
663
Coagulopathy prediction in traumatic brain injury
Evangelos Kalogirou1, Spyridon Voulgaris1, George A Alexiou1
1Department of Neurosurgery, University of Ioannina, School of Medicine, Ioannina Greece.
Advances in Clinical Chemistry
|April 4, 2025
Summary
Biomarkers like glucose, interleukin-33, and galectin-3 show promise in detecting traumatic brain injury (TBI) complications such as coagulopathy and progressive hemorrhagic injury (PHI). Further research is needed for clinical application.
Area of Science:
- Neuroscience
- Biochemistry
- Clinical Medicine
Background:
- Traumatic brain injury (TBI) is a major public health issue.
- TBI causes secondary damage via inflammation, leading to coagulopathy.
- TBI-induced coagulopathy affects 32.7% of patients, increasing mortality and poor outcomes.
Purpose of the Study:
- Investigate biomarkers for detecting TBI-induced coagulopathy and progressive hemorrhagic injury (PHI).
- Evaluate biomarker utility using statistical evidence.
- Explore biomarker associations with TBI biochemical processes.
Main Methods:
- Systematic review and meta-analysis of existing studies.
- Statistical evaluation of biomarker sensitivity and specificity.
- Exploration of biochemical pathways involved in TBI complications.
Main Results:
- Glucose demonstrates high sensitivity (91.5%) and specificity (87.5%) for predicting coagulopathy.
- Interleukin-33 shows high sensitivity (93.3%) but lower specificity (66.7%) for PHI.
- Galectin-3 exhibits moderate sensitivity (67.7%) and high specificity (85.5%) for PHI.
Conclusions:
- Biomarkers show potential for diagnosing TBI-related coagulopathy and PHI.
- Clinical translation requires further research and validation.
- Refining biomarker application can improve TBI patient management and outcomes.
